---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-054341"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-08-06T20:16:48+00:00"
generated_at: "2026-08-06T20:19:18.087180+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen Phase 2 fasedienol study: safety met, numerical separation on primary; nominally significant in severe SAD

## Summary
- Safety objective met: repeat dose fasedienol safety comparable to single dose, no new findings.
- Primary endpoint (SUDS change) numerical separation from placebo but not statistically significant (pooled p=0.2).
- In very severe SAD (LSAS≥95), pooled fasedienol showed nominally significant improvement (p=0.04, Cohen's d=0.78).
- CGI-I and PGI-C responder rates directionally higher for fasedienol; repeat dose arm >2x placebo.
- Exploratory anticipatory anxiety endpoint: repeat dose (p=0.01) and pooled (p=0.03) nominal significance.

## SEC filing metadata
- accession: 0001628280-26-054341
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-08-06T20:16:48+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026054341/0001628280-26-054341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026054341/vtgn-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-054341
- JSON: https://secwatch.observer/filing/0001628280-26-054341.json
- Plain text: https://secwatch.observer/filing/0001628280-26-054341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.